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The new generation broadly neutralizing antibody VRC01 against HIV-1 shows great potential as
a topically administered microbicide to prevent sexual transmission. We evaluated its efﬁcacy in a
RAG-hu humanized mouse model of vaginal HIV-1 transmission. Mice were challenged vaginally with
R5 tropic HIV-1 BaL an hour after intravaginal application of the VRC01 (1 mg/ml concentration) gel.
A combination of four ﬁrst generation bNAbs, namely b12, 2F5, 4E10 and 2G12, was used as a positive
efﬁcacy control whereas a non-speciﬁc dengue MAb 4G2 was used as negative control. Our results
showed that seven out of nine VRC01 antibody administered mice and all of the mice receiving the four
bNAb antibody combination were protected against HIV-1 challenge. These ﬁndings demonstrate the
efﬁcacy of the new bNAb VRC01 as a topical microbicide to protect against HIV-1 vaginal transmission
and highlight the use of the RAG-hu mouse model for testing HIV prevention strategies.
& 2012 Elsevier Inc. All rights reserved.Introduction
HIV incidence continues to be unabated worldwide in the
absence of an effective vaccine (UNAIDS (Website)). Therefore
there is an urgency to develop alternative prevention methods to
contain this epidemic. In this regard, topically applied microbicide
gels to prevent sexual transmission show considerable promise
(Lederman et al., 2008; Omar and Bergeron, 2011; Shattock and
Rosenberg, 2012) While a number of early clinical trials using
non-speciﬁc compounds such as nonoxynol-9 failed to show
protection, the recent success achieved with the RT inhibitor
tenofovir gel in the CAPRISA004 trial provided renewed optimism
in the microbicide ﬁeld (Abdool Karim et al., 2010; Abdool Karim
and Baxter, 2012). Based on this success, the current strategies are
focused on using HIV speciﬁc compounds that act against differ-
ent stages of the viral life cycle. These include entry inhibitors
such as maraviroc, nucleoside and non-nucleoside reverse tran-
scriptase inhibitors like tenofovir and TMC 120 and integrase
inhibitors exempliﬁed by raltegravir, to name a few (Shattock and
Rosenberg, 2012). Successful development and deployment of anll rights reserved.
.effective anti-HIV microbicide will empower women to protect
themselves against contracting the infection and thus is esti-
mated to prevent millions of new cases of HIV.
In practice, prevention of HIV infection by the use of micro-
bicides involves repeated applications of the gels that contain
high concentrations of anti-HIV compounds of various chemis-
tries (Hladik and Doncel, 2010; Kelly and Shattock, 2011; Klasse
et al., 2006). It is possible that such a repeated exposure of
sensitive cervico-vaginal mucosal tissues to these drugs during
long-term use may result in toxicities causing epithelial damage
eventually undermining the protective effects. In this regard, use
of biomolecules such as neutralizing antibodies may circumvent
potential damage to the mucous membranes thus affording long-
term safety. Additionally, combining these with that of other anti-
HIV compounds may permit reducing the concentrations of the
respective compounds to lower and much safer levels. Given the
extensive antigenic variability of HIV-1, any candidate antibody
has to be broadly neutralizing to qualify as an effective micro-
bicide to prevent infection. Until recently, studies in this area
have been limited due to sparse numbers of available potent
broadly neutralizing antibodies (bNAbs) (Hessell et al., 2009a,
2010; Parren et al., 2001; Veazey et al., 2003). This limitation is
now overcome by the discovery of several new more potent
bNAbs (Mascola and Monteﬁori, 2010; Walker et al., 2009;
Fig. 1. Vaginal application of VRC01 gel protects humanized mice against vaginal
HIV-1 challenge. RAG-hu mice were challenged by vaginal route 1 h after vaginal
administration of VRC01, combinatorial bNAb, irrelevant antibody or placebo gels
as described in Materials and methods. Blood was collected bi-weekly from
infected mice and the status of HIV-1 infection was determined by qRT-PCR.
Kaplan–Meier plots of time course of appearance of viremia in antibody treated
versus non-treated virus challenged mice.
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microbicide potential was derived by the studies of Veazey
et al. (2003) in a monkey model. Animals were administered a
bNAb antibody b12 vaginally in either saline or hydroxyethyl
cellulose gel . Only three out of 12 treated and SHIV challenged
animals became infected and it was found that the duration of
protection lasts for at least two hours after administration. These
results form a sound basis that neutralizing antibodies have good
microbicide potential.
While the previous generation bNAbs such as b12, 2G12, 2F5,
and 4E10 were shown to be capable of neutralizing many primary
HIV-1 isolates belonging to multiple genetic subtypes, they are
not pan-reactive (Mascola and Monteﬁori, 2010). In recent studies
directed towards ﬁnding more bNAbs with an ultimate goal of
designing better vaccines, newer high throughput strategies were
used (Walker et al., 2009; Wu et al., 2010). These studies have led
to the discovery of more highly potent neutralizing antibodies.
These include bNAbs PG9, PG16, HJ16 and VRC01, among others.
While b12 and HJ16 can neutralize about 40% of known viral
isolates, PG9 and PG16 bNAbs neutralized 73% and 79% of viral
isolates tested respectively (Corti et al., 2010; Walker et al., 2009).
The bNAb VRC01 that recognizes the CD4 binding site on HIV
gp120 showed even more potency and breadth with a capacity to
neutralize 91% of viral strains tested (Wu et al., 2010). With these
successes as a background, a more intensiﬁed search recently
yielded even more potent bNAbs such as multiple PGT bNAbs
recently discovered by Walker et al. (2011). The availability of
these antibodies opened up many new avenues of HIV therapies
and prevention including microbicides.
With regard to testing microbicide strategies in vivo using
bNAbs as well as other anti-HIV compounds, macaque models
have been the leading standard (Veazey et al., 2012). They
were instrumental for the basic groundwork and provided the
preliminary efﬁcacy data for subsequent human clinical trials.
However, they are expensive, and cannot use HIV-1 itself for
testing and therefore rely on SIV and/or varieties of hybrid SHIV
viruses for viral challenge (Denton and Garcia, 2009, 2011; Hladik
and Doncel, 2010; Klasseet al., 2008). Furthermore, it is not
possible to test against drug resistant and genetically diverse
HIV-1 strains that exist in the ﬁeld. Some of these deﬁciencies can
now be overcome by the newer generation humanized mouse
models that have emerged (Berges and Rowan, 2011; Denton and
Garcia, 2009; Shultz et al., 2011). These include RAG-hu mice and
BLT mice which were found to have HIV susceptible human cell
reconstitution in cervico-vaginal and rectal mucosal compart-
ments (Berges et al., 2008; Sun et al., 2007). A number of recent
studies have demonstrated their susceptibility to HIV-1 infection
by both vaginal and rectal routes (Akkina et al., 2011; Berges
et al., 2008; Denton et al., 2008; Neff et al., 2011). Exploiting this
property, indeed both pre-exposure prophylaxis and microbicide-
based prevention of HIV-1 mucosal transmission has recently
been shown using these models by us and others (Denton et al.,
2011; Neff et al., 2011, 2010). More recently we validated the
RAG-hu mouse model for vaginal microbicide testing using
maraviroc which showed good efﬁcacy (Neff et al., 2011).
With the advent of new discoveries that continuously yield
a stream of newer and more potent bNAbs and other new
biological molecules for potential use as microbicides, it is impor-
tant that promising candidates need to be evaluated quickly and
inexpensively for generating preliminary data for later macaque
studies and human clinical trials. With these questions as a back-
ground, we conducted the following proof-of-concept studies to
evaluate bNAb VRC01 as a potential microbicide. Our results show
that these antibodies confer signiﬁcant protection against HIV-1
vaginal challenge and that RAG-hu mice provide a suitable in vivo
system to test biomolecules as potential anti-HIV microbicides.Results
Vaginal application of VRC01 gel confers protection against HIV-1
vaginal challenge in RAG-hu mice
We have previously shown that RAG-hu mice are susceptible
to vaginal HIV-1 transmission and can be used to test both oral
PrEP and topically administered anti-HIV compounds, namely
the CCR5 inhibitor maraviroc and integrase inhibitor raltegravir
(Neff et al., 2011, 2010). Here we evaluated a biological molecule
VRC01, a broadly neutralizing monoclonal antibody, for its ability
to protect humanized mice against HIV-1 vaginal challenge. Mice
were monitored by qRT-PCR on a bi-weekly basis for ten weeks to
detect virus in the plasma of virally challenged mice. As a positive
effective control, a gel containing a cocktail of four bNAbs, b12,
4E10, 2F5 and 2G12 antibodies, was employed. Our results (Fig. 1)
showed that all the mice (6/6) receiving either a placebo gel
(no antibodies) or a gel containing an irrelevant anti-dengue MAb
(4/4) became virus positive within ﬁve and three weeks post-viral
challenge, respectively. In contrast, in the VRC01 treated group
only two out of nine mice (2/9) became virus positive, showing
signiﬁcant protection. In mice receiving the bNAb cocktail of four
antibody combination, none were infected (0/5) thus showing
complete protection. In mice which were not virally challenged,
as expected, no virus could be detected (0/2). With regard to
viremia, unprotected mice receiving placebo gel, irrelevant non-
speciﬁc antibody gel as well as non-protected mice in the VRC01
treated group exhibited persistent viremia after becoming virus
positive (Fig. 2). Overall, these data indicate that VRC01 bNAb
confers signiﬁcant protection against HIV-1 vaginal challenge
when compared to placebo and 4G2 non-speciﬁc antibody treated
RAG-hu mice, with P values of 0.0013 and 0.002, respectively.
Additionally, when comparing VRC01 and bNAb cocktail treated
mice, a P value of 0.2774 indicates that there is no signiﬁcant
difference between these two bNAb treated groups. These data
taken together suggest that VRC01 bNAb conferred partial but
signiﬁcant protection and the combinatorial antibody gel pro-
vided full protection.
CD4 T cell loss in placebo-gel administered and non-protected versus
VRC01 protected RAG-hu mice
The RAG-hu mouse model mimics the immunopathology of
HIV-1 infection in humans, as demonstrated by virally mediated
depletion of CD4 T cells. While the qRT-PCR data detected no
viremia in microbicide gel protected mice, we wanted to further
conﬁrm that there is no evidence of HIV induced pathology as can
Fig. 2. Viral RNA loads in mice administered with different bNAb gels. RAG-hu
mice were challenged by vaginal route an hour after vaginal application of bNAb
gels as described in Materials and methods. Blood was collected bi-weekly. Viral
RNA was extracted from plasma and viral RNA loads were determined by qRT-PCR
as described in Materials and methods. The dotted line represents limit of PCR
detection.
Fig. 3. CD4 T cell decline in non-protected mice versus protected mice. Levels of
CD4 T cells were monitored bi-weekly by FACS to determine their decline in
treated versus non-treated mice. Baseline values for each of the mice were
established prior to infection as described in Materials and methods and are
shown as week 0 values.
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blood from virally challenged mice was evaluated periodically by
FACS analysis for 10 weeks (Fig. 3). The baseline CD4 T cell levels
were established prior to viral challenge in each of the mice.
Typical of HIV-1 infection of these mice, there was a trend of
gradual CD4 T cell decline in the irrelevant antibody (4G2)
gel treated mice in which viremia was seen. On the contrary,
no discernible CD4 T cell loss could be seen in either VRC01
protected or bNAb cocktail gel treated mice. Consistent with the
presence of viremia in the two VRC01 mice that became virus
positive and were thus deemed non-protected, there was sig-
niﬁcant CD4 T cell loss. Collectively these data showed that the
mice which did not become virus positive also did not show any
HIV associated CD4 T cell loss.Discussion
A safe and effective microbicide which women can use to
protect themselves against contracting HIV infection would
greatly help diminish the disease incidence. If found to be
effective, use of naturally occurring biological molecules such as
antibodies will have considerable edge over other chemical
compounds in terms of assuring long term safety and reducing
side effects. Here in these preliminary studies we have shown
that a new generation potent broadly neutralizing monoclonalantibody VRC01 confers signiﬁcant protection against HIV-1
vaginal transmission. To our knowledge this is the ﬁrst report to
show the efﬁcacy of the new generation bNAbs as potential HIV
microbicides in an in vivo system using HIV-1 itself as the
challenge virus. While a number of previous macaque studies
using previous generation of bNAb have shown their utility as
microbicides (Ferrantelli et al., 2004; Hessell et al., 2009a,b, 2010;
Hofmann-Lehmann et al., 2002; Ruprecht et al., 2001; Veazey
et al., 2003), the humanized mouse system we used here per-
mitted efﬁcacy testing in the context of human target cells. Also,
unlike in macaque studies, there was no need to condition the
animals by progesterone hormonal treatment with Depo-Provera
to induce vaginal thinning.
The new generation microbicide compounds are being chosen
for their speciﬁc inhibitory effects on various stages of the viral
life cycle in contrast to previous generation generic non-speciﬁc
agents (Ferguson and Rohan, 2011; Omar and Bergeron, 2011).
The recently ﬁeld tested RT inhibitor microbicide compounds
such as tenofovir showed promising efﬁcacy but still fall short
of the desired full protection level (Abdool Karim et al., 2010).
The inhibitors such as RT and integrase inhibitors would act after
viral entry (Klasse et al., 2008; Omar and Bergeron, 2011). If the
drug levels are insufﬁcient intracellularly in a small sub-popula-
tion of cells, virus breakthrough is likely. Therefore, if possible it is
highly desirable to prevent the ﬁrst step of viral entry in the viral
life cycle. In this regard, compounds such as maraviroc, a CCR5
antagonist, have been shown to prevent vaginal transmission of
SHIV virus in macaque studies (Veazey et al., 2010). We have
recently shown its anti-HIV microbicide potential in a humanized
mouse system similar to the one we used here (Neff et al., 2011).
While the inhibitory activity of RTIs is not co-receptor dependent,
use of a single entry inhibitor like CCR5 antagonist maraviroc
alone will be ineffective against X4 and dual tropic viruses which
are transmitted, albeit at a low level. An advantage of bNAbs in
the context of entry inhibitors is that they are effective against all
HIV-1 strains irrespective of their co-receptor tropism.
Among bNAbs, VRC01 antibody is the most potent and most
broadly neutralizing with activity against 91% of viruses tested
(Wu et al., 2010). In our present study seven out of nine vaginally
challenged mice were protected against HIV-1 infection at 1 mg/ml
concentration of the topically applied gel. While the protection
conferred is signiﬁcant, it is not complete. It is possible that a
higher concentration of VRC01 may be needed for complete
protection. Alternatively an improved formulation that reduces
possible biodegradation in the cervico-vaginal environment may
improve its efﬁcacy. Moreover, if better retention can be achieved
using alternative gel formulations, lower doses of VRC01 might
offer the same or higher level of protection, compared to the dose
tested here. A recent preliminary report by Pegu et al. (Meeting
Abstract Supplement, J. Immunol. April 2011, 186, 155.11)
described the protective effect of passively transferred VRC01.
In this study, macaques were administered with VRC01 systemi-
cally by i.v. route (dose 20 mg/kg). Two days later they were
either challenged by vaginal or rectal routes with a SHIV virus.
Whereas 3/4 animals got infected in the control groups by both
the routes none of the animals (4/4) that received VRC01 were
infected by either route thus showing full protection. This data
demonstrated that passively administered VRC01 antibody pro-
vides sterilizing mucosal immunity.
The microbicide formulation containing a mix of bNAbs 2G12,
4E10, 2F5 and b12 which we used as positive efﬁcacy control in
this study provided complete protection in which ﬁve out of ﬁve
animals were protected. This result is consistent with other
studies that showed high level of protection by the combination
of the bNAbs listed above in different in vivo and in vitro settings
(Ferrantelli et al., 2004; Gauduin et al., 1997; Hessell et al.,
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Parren et al., 2001; Ruprecht et al., 2001; Veazey et al., 2003). This
complete protection offered by the combination of four bNAbs
with different target epitopes points to the important fact already
recognized in the ﬁeld—combinatorial approaches are needed for
future microbicide formulations and the principle of using multi-
ple antiviral agents must be adopted, keeping in mind the success
of HAART therapy for already established HIV-1 infections. In a
study pointing to the combinatorial approach by Euler et al.
(2011) in which viral isolates from the early stages of HIV-1
epidemic as well as from recent years were tested against VRC01,
PG16 and PG8 bNAbs it was found that, even though resistance
developed over time for all the bNAbs tested, every strain
included in the panel showed high sensitivity to at least one of
the bNAbs. A new study by West et al. (2011) showed that a
construct which combines VRC01 scFv (single chain Fragment
variable) and PG16 IgG yields a potent chimera with greater
neutralization breadth thus opening the door for new modes of
combining bNAbs with different gp120 epitopes in the future.
In addition to combinatorial approaches, efforts to engineer
newer bNAbs with increased potency and breadth based on the
structure of VRC01 are already under way (Scheid et al., 2011;
Wu et al., 2011).
Since the present data demonstrated the efﬁcacy of the new
generation bNAbs as potential microbicides against HIV-1 infec-
tion, a number of other important questions need to be evaluated.
Among these are—if combining these with other antibodies
and/or with other ARVs will increase the efﬁcacy and breadth of
action. For these antibodies to reach wider application in the ﬁeld
as microbicides and to be used by millions of people at risk, it is
necessary that they need to be mass produced in the required
quantities. This is being currently addressed by newer mass
production methods such as utilizing genetically engineered
plants (Fox, 2011). However, possible immunogenicity of plant-
expressed molecules and concerns regarding genetically engi-
neered plants in some quarters would need to be resolved for
their wider use and acceptance. With regard to large scale testing
of a wide variety of biological molecules and chemical ARDs in the
future to derive preclinical data, the humanized mouse model we
employed here will offer a rapid cost effective in vivo model.Table 1
Summary of human cell engraftment levels in humanized mice. Peri
RAG-hu mice (BALB/c-RAG2-/-gc-/- or BALB/c-RAG1-/-gc-/-, the preﬁx
blood cell fraction was stained with CD45 FITC conjugated antibody a
treatment and vaginal HIV-1 challenges.
VRC01 mouse no. Engraftment (%)
J961 58
J975 59.3
J977 67.3
J978 63.6
J996 54.1
J997 50.9
J998 52.1
J1033 72.9
J1035 77
bNAb cocktail mouse no. Engraftment (%)
J909 69.5
J911 78.5
J981 54.2
J985 73.8
J989 55.4
Negative control mouse no. Engraftment (%)
932 62.9
933 68.2Materials and methods
Generation of humanized Rag1-/- gc-/- and Rag2-/- gc-/-mice
(RAG-hu mice)
Humanized BALB/c- Rag1-/- gc-/- and BALB/c- Rag2-/- gc-/-
(RAG-hu) mice were generated using human fetal liver-derived
CD34þ hematopoietic progenitor cells as previously described
(Akkina et al., 2011; Berges et al., 2008, 2010, 2006). Mice were
maintained at the Colorado State University Painter Animal
Center and all studies have been reviewed and speciﬁcally
approved by the CSU Institutional Animal Care and Use Commit-
tee (Protocol 09-085A). Newborn mice were preconditioned by
irradiating with a sublethal dose of 350 rad and then injected
intrahepatically with 0.5–1106 human CD34þcells. Mice were
screened for human cell engraftment at 10–12 weeks post-
reconstitution. Peripheral blood was collected by tail bleed and
red blood cells were lysed by the Whole Blood Erythrocyte Lysing
Kit (R&D Systems, Minneapolis, MN). The white blood cell fraction
was stained against the human pan-leukocyte marker CD45 using
hCD45-R-PE (Invitrogen) and FACS analyzed to determine the
levels of human cell engraftment as previously reported (Berges
et al., 2006). All mice included in the study were monitored for
level of engraftment prior to the beginning of the experiment.
Female mice prepared with different donor CD34þ cells with
over 50% engraftment were randomly distributed into experi-
mental and control groups.
Vaginal application of bNAb VRC01 gel and HIV-1 challenge
by vaginal route
VCR01 antibody was kindly provided by Vaccine Research
Center (VRC), NIAID, NIH, and older generation bNAbs 2G12,
b12, 4E10 and 2F5 were obtained from NIH AIDS Research &
Reference Reagent Program. To prepare a topical gel formulation
VRC01 antibody was incorporated into a 2.2% hydroxy ethyl cellu-
lose (HEC) universal placebo gel at a concentration of 1 mg/ml.
As a positive effective control, a four bNAb antibody mix was
employed. This combinatorial bNAb cocktail gel formulation was
prepared by using old generation bNAb antibodies of differentpheral blood was collected from human CD34 cell reconstituted
J is indicative of RAG1) at 10–12 weeks post-engraftment. White
nd analyzed by FACS to conﬁrm human cell engraftment prior to
Placebo mouse no. Engraftment (%)
1000 78.1
997 70.4
944 74.7
945 63.7
J1008 67.6
J1009 87
4G2 control mouse no. Engraftment (%)
J1010 63.2
J1011 69.2
J1012 78.4
J1013 59.8
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all incorporated into the 2.2% HEC gel at a ﬁnal concentration of
0.125 mg/ml for each antibody in the mix (0.5 mg/ml total anti-
body ﬁnal concentration). We also prepared a gel with a negative
control bNAb (1 mg/ml) using an irrelevant non-HIV-1 antibody
4G2 (a mAb against dengue virus). For these experiments we used
mice that have human CD45 cell engraftments of 50% or more
(Table 1). Female RAG-hu mice were topically administered with
VRC01 gel (nine mice), bNAb cocktail gel (ﬁve mice) or control
4G2 gel (four mice) an hour before the viral challenge. A 25 ml
volume of each of the gel formulations was carefully applied into
the vaginal vault of RAG-hu mice. During the whole procedure
mice were anesthetized by isoﬂurane inhalation (duration
7–10 min). An hour post-gel application, mice were challenged
vaginally with HIV-1 BaL (3000 TCID) in a 25 ml volume. Gel and
viral inoculums were applied by using the bulbous end (1.25 mm
in diameter) of a gavage needle (VWR, POPPER, NY) to assure no
mucosal abrasions and tearing would occur (Neff et al., 2011).
Anesthetized mice were held in an inverted position for 4 min
post-inoculation to allow the virus to adsorb and to prevent
immediate discharge of virus, as described previously (Berges
et al., 2008; Neff et al., 2010). Control non-treated mice received
2.2% HEC placebo gel. Animals were observed daily and blood
samples collected on a weekly basis to assess plasma viremia and
CD4 T cell counts.
Measurement of viral loads
HIV-1 infection status and viral loads were assessed by
qRT-PCR. RNA was extracted from 25 to 50 ml of EDTA-treated
plasma using the QIAamp Viral RNA kit (Qiagen, Valencia, CA).
qRT-PCR was performed by using a primer set speciﬁc for the HIV-
1 LTR sequence and a corresponding LTR speciﬁc probe as
described previously (Berges et al., 2008, 2010). C1000 Thermal
Cycler (CFX96TM Real-Time System, BIO-RAD) and iScriptTM One-
Step RT-PCR kit with SYBRs Green (BIO-RAD) were used to
perform the real-time qPCR analysis and viral load was expressed
as the number of HIV-1 RNA copies per milliliter plasma.
Flow cytometry
Mice were monitored biweekly to analyze the levels of CD4 T
cells in the peripheral blood. Whole blood was collected and red
blood cells lysed as described previously (Berges et al., 2010, 2006).
Peripheral lymphocytes were stained for hCD45-FITC, hCD3-R-PE
and hCD4-PE-Cy5 surface markers (Invitrogen, BD Biosciences) and
monitored using a Coulter EPICS XL-MCL FACS analyzer (Beckman
Coulter, Fullerton, CA). CD4þ T cell levels were calculated as a ratio
of the entire CD3 population (CD4þCD3þ:CD4–CD3þ). All mice
were screened prior to the gel application and HIV-1 challenge to
establish baseline CD4 T cell ratios.
Statistics
Data regarding the number of viral RNA copies, CD4 T cell
levels, and infection rates was analyzed using GraphPad Prism
version 5 (GraphPad Software, USA). To compare the infection
rates between the groups, Fisher’s Exact test was applied for
analysis of the percent infected curves. P values less than 0.05
were considered to be signiﬁcant.Acknowledgments
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